Sugi Predict

Sugi Predict / Targets / CHRNA9

CHRNA9

Neuronal acetylcholine receptor subunit alpha-9 · Q9UGM1 · CHRNA9 on Sugi Atlas →

10,484 patent compounds predicted against CHRNA9, 6,618 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Iodide Iodide (SCHEMBL1019297) 0.58 9/20
SCHEMBL584752 SCHEMBL584752 0.43 7/20
SCHEMBL80826 SCHEMBL80826 0.63 6/20
Stilonium Stilonium (SCHEMBL26104) 1.00 5/20
Stilonium Stilonium (SCHEMBL26105) 1.00 5/20
SCHEMBL1618632 SCHEMBL1618632 0.67 5/20
Iodide Iodide (SCHEMBL1320371) 0.62 5/20
SCHEMBL1321703 SCHEMBL1321703 0.59 5/20
SCHEMBL1663972 SCHEMBL1663972 0.58 5/20
SCHEMBL81218 SCHEMBL81218 0.58 5/20
SCHEMBL81293 SCHEMBL81293 0.57 5/20
SCHEMBL123740 SCHEMBL123740 0.55 5/20
SCHEMBL1226431 SCHEMBL1226431 0.52 5/20
SCHEMBL1126920 SCHEMBL1126920 0.50 5/20
SCHEMBL1535035 SCHEMBL1535035 0.45 5/20
SCHEMBL677293 SCHEMBL677293 0.45 5/20
SCHEMBL677083 SCHEMBL677083 0.44 5/20
SCHEMBL677499 SCHEMBL677499 0.44 5/20
SCHEMBL123118 SCHEMBL123118 0.52 4/20
Bromide Bromide (SCHEMBL1087062) 0.51 4/20

Clinical trials — most relevant to CHRNA9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Galantamine for Cognition in People With Schizophrenia PHASE4COMPLETED
Efficacy of the Use of Genetic Markers in the Choice of the Pharmacological Treatment of Smoking (GENTSMOKING) PHASE4COMPLETED
The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease PHASE4COMPLETED
Efficacy Study of Galantamine for Cognitive Impairments in Schizophrenia PHASE4COMPLETED
Postoperative Sugammadex After COVID-19 PHASE4UNKNOWN
Transcranial Magnetic Stimulation in Patients with Dual Disorders PHASE3NOT_YET_RECRUITING
Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease Experiments 1 & 2 - Proj #3 PHASE2COMPLETED
Crossover Target Engagement Study of Cholinergic Mechanisms of Gait Dysfunction in Parkinson's Disease (Project #3 - Experiment 3 [UdallP3E3]) PHASE2COMPLETED
Nicotinic Receptors and Schizophrenia PHASE1/PHASE2WITHDRAWN
Varenicline (Chantix™) for the Treatment of Alcohol Dependence PHASE2COMPLETED
Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia PHASE2COMPLETED
Safety and Efficacy of MEM 3454 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism PHASE1/PHASE2COMPLETED
Nicotinic Receptor Genetic Variation and Alcohol Reward PHASE1RECRUITING
Brain Networks and Addiction Susceptibility PHASE1COMPLETED
The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine PHASE1WITHDRAWN
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals PHASE1COMPLETED
Gene Therapy for Alzheimer's Disease Clinical Trial PHASE1COMPLETED
Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression nanCOMPLETED
Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia nanUNKNOWN
Effects of Prazosin on the Attention-Enhancing Effects of Nicotine nanWITHDRAWN
Neural Inhibition as a Mechanism of Nicotine Dependence Among Persons With Schizophrenia nanCOMPLETED
Nicotinic Receptor Levels After Stopping Smoking nanCOMPLETED
fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia nanCOMPLETED
Brain Imaging in Alzheimer's Disease nanCOMPLETED
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients nanCOMPLETED
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection nanCOMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging nanACTIVE_NOT_RECRUITING
A Study on Risk Mutations of Vulnerability Genes of Schizophrenia nanUNKNOWN
Preemptive Oral Gabapentin and Tramadol on Postoperative Pain After Knee Arthroscopy nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CHRNA9 binder may also engage these)

ProteinNameSimilarity
P43144 — 1.000 P43144 →
Q9PTS8 — 0.994 Q9PTS8 →
P04759 — 0.985 P04759 →
Q68RJ7 — 0.983 Q68RJ7 →
P02717 — 0.983 P02717 →
P25110 — 0.981 P25110 →
P49580 — 0.977 P49580 →
P02714 — 0.976 P02714 →
P19370 — 0.975 P19370 →
P54131 — 0.974 P54131 →
P02716 — 0.974 P02716 →
Q05941 — 0.974 Q05941 →
Q8JFN7 — 0.973 Q8JFN7 →
P05376 — 0.972 P05376 →
P26153 — 0.972 P26153 →
P49582 — 0.971 P49582 →
CHRNA7 Neuronal acetylcholine receptor subunit alpha-7 0.970 landscape →
P22770 — 0.970 P22770 →
P09484 — 0.969 P09484 →
CHRND Acetylcholine receptor subunit delta 0.969 landscape →
P02713 — 0.968 P02713 →
Q866A2 — 0.967 Q866A2 →
Q494W8 — 0.967 Q494W8 →
P09628 — 0.966 P09628 →
P02718 — 0.965 P02718 →
Q8SPU6 — 0.964 Q8SPU6 →
CHRNB2 Neuronal acetylcholine receptor subunit beta-2 0.964 landscape →
Q08832 — 0.962 Q08832 →
P26714 — 0.961 P26714 →
P02712 — 0.960 P02712 →